Gene Therapy Shows Long-Term Benefit in Hemophilia B

Posted: 2025-04-16 23:05:40 UTC

@NEJMNEJM

#genetherapy

#medicalresearch

#hemophiliaB

#factorIX

#bleedingdisorders

Read With Caution

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Full Thread

This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.

Read With Caution

Verification Details

Status

In Progress

VerifiedPartially VerifiedFalse

Last Updated

2025-04-16 23:05:55 UTC

Verified By

Rollup News

TL;DR;

A long-term study showed that a single dose of fidanacogene elaparvovec significantly reduced bleeding rates in hemophilia B patients by sustaining factor IX expression in liver cells.

Key Impact Areas

Sustained factor IX expression

Reduced annualized bleeding rates

Single-dose effectiveness

Gene Therapy Shows Long-Term Benefit in Hemophilia B

Read With Caution

Full Thread

Read With Caution

Verification Details

TL;DR;

Key Impact Areas

Claims

Deliberation Map

Similar Rollups